Akari Therapeutics, Plc (AKTX) Earnings History
Annual and quarterly earnings data from 2010 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export AKTX earnings history in CSV or JSON format
Free sign-in required to download data
Akari Therapeutics, Plc (AKTX) Earnings Overview
As of February 28, 2026, Akari Therapeutics, Plc (AKTX) reported trailing twelve-month net income of -$16M, reflecting -7.3% year-over-year growth. The company earned $-48262.47 per diluted share over the past four quarters.
Looking at the long-term picture, AKTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$675,000 in fiscal 2010.
Akari Therapeutics, Plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), ABVX (-$332M net income, -16.3% margin), AKTX has comparable earnings metrics. Compare AKTX vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$20M | -97.8% | -$22M | $-1660.00 | - | - |
| 2023 | -$10M | +43.6% | -$17M | $-200.00 | - | - |
| 2022 | -$18M | -1.9% | -$23M | $-220.00 | - | - |
| 2021 | -$17M | -2.0% | -$17M | $-820.00 | - | - |
| 2020 | -$17M | -1.4% | -$18M | $-1120.00 | - | - |
| 2019 | -$17M | +15.6% | -$25M | $-2380.00 | - | - |
| 2018 | -$20M | +28.6% | -$20M | $-2520.00 | - | - |
| 2017 | -$28M | -53.9% | -$35M | $-4480.00 | - | - |
| 2016 | -$18M | +60.0% | -$27M | $-3080.00 | - | - |
| 2015 | -$45M | -369.7% | -$31M | $-10640.00 | - | - |
See AKTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AKTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AKTX vs AGIO
See how AKTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AKTX growing earnings?
AKTX EPS fell to $-48262.47, with earnings declining -7.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-16M.
What are AKTX's profit margins?
Akari Therapeutics, Plc net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are AKTX's earnings?
AKTX earnings data spans 2010-2024. The declining earnings trend is -7.3% YoY. Historical data enables comparison across business cycles.